Writing the Future of Biologics (PEGS Boston 2022)

Aaron Sato, CSO

View the Webinar

Presented by

Aaron Sato

Twist Bioscience

RECORDED AT PEGS Boston 2022

Covered in this Webinar

The Twist Discovery Stack - synthetic phage display libraries, in vivo immunization & artificial intelligence-aided Ab engineering

Case Study 1 - Adenosine Pathway Targets Master Checkpoint in Tumor Microenvironment (TME)

Case Study 2 - Use of Immune Repertoires to Design a Target Focused Library

Tools for Engineering CARs and TCRs

Twist Biopharma, a division of Twist Bioscience, combines high-throughput DNA synthesis technology with deep expertise in antibody engineering to provide end-to-end antibody discovery solutions — from gene synthesis to antibody optimization. The result is a make-test cycle that yields better antibodies against more diverse and challenging targets. Twist Biopharma will continue to optimize and expand its library synthesis and screening capabilities in partnership with other discovery technologies to further utilize the Twist make-test cycle.

Share your details to Watch the Webinar

Genes

Oligo Pools

NGS Target Enrichment Solutions

Variant Libraries

Synthetic Controls

Antibody Discovery

Writing the Future of Biologics (PEGS Boston 2022)

Related Resources

Writing the Future of Cell Therapies

Twist GPCR Library Series Unlock the G-protein coupled receptor (GPCR) interactome for antibody discovery

Leveraging synthetic Library of Libraries to enable effective antibody discovery against high-impact targets